Theriva Biologics KOL Event on Elevating the Antitumor Immune Response: Use of VCN-01 to Improve Outcomes with Checkpoint Inhibitors in Patients with Refractory Head and Neck Cancer
About The Event
Join us for a virtual KOL event with Theriva Biologics, featuring expert oncologist Ricard Mesia, MD (Institut Català d’Oncologia / Catalan Institute of Oncology) who will discuss the unmet medical needs in head and neck cancer, current treatment limitations, and the need for new approaches, along with key takeaways from his team’s ESMO poster presentation describing the use of Theriva’s VCN-01 in combination with a checkpoint inhibitor in refractory head and neck cancer patients.
Theriva leadership will provide a pipeline update, along with insight into their clinical development strategy for VCN-01-based combination approaches to treat challenging cancers. VCN-01 is Theriva’s systemic, selective, stroma-degrading oncolytic adenovirus.
A live question and answer session will follow the formal presentations.